Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count

Amanda Mocroft; Peter Reiss; Ole Kirk; Cristina Mussini; Enrico Girardi; Philippe Morlat; Christoph Stephan; Stephane De Wit; Katja Doerholt; Jade Ghosn; Heiner C Bucher; Jens D Lundgren; Genevieve Chene; Jose M Miro; Hansjakob Furrer; Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE)

doi:10.1086/655761

Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count

Amanda Mocroft, Peter Reiss, Ole Kirk, Cristina Mussini, Enrico Girardi, Philippe Morlat, Christoph Stephan, Stephane De Wit, Katja Doerholt, Jade Ghosn, Heiner C Bucher, Jens D Lundgren, Genevieve Chene, Jose M Miro, Hansjakob Furrer, Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE)

100 Citationer (Scopus)

Abstract

Current guidelines suggest that primary prophylaxis for Pneumocystis jiroveci pneumonia (PcP) can be safely stopped in human immunodeficiency virus (HIV)-infected patients who are receiving combined antiretroviral therapy (cART) and who have a CD4 cell count >200 cells/microL. There are few data regarding the incidence of PcP or safety of stopping prophylaxis in virologically suppressed patients with CD4 cell counts of 101-200 cells/microL.

Originalsprog	Engelsk
Tidsskrift	Clinical Infectious Diseases
Vol/bind	51
Udgave nummer	5
Sider (fra-til)	611-9
Antal sider	9
ISSN	1058-4838
DOI	https://doi.org/10.1086/655761
Status	Udgivet - 1 sep. 2010

Adgang til dokumentet

10.1086/655761

Andre filer og links

Link to publication in Scopus

Citationsformater

Mocroft, A., Reiss, P., Kirk, O., Mussini, C., Girardi, E., Morlat, P., Stephan, C., De Wit, S., Doerholt, K., Ghosn, J., Bucher, H. C., Lundgren, J. D., Chene, G., Miro, J. M., Furrer, H., & Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) (2010). Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count. Clinical Infectious Diseases, 51(5), 611-9. https://doi.org/10.1086/655761

Mocroft, A, Reiss, P, Kirk, O, Mussini, C, Girardi, E, Morlat, P, Stephan, C, De Wit, S, Doerholt, K, Ghosn, J, Bucher, HC, Lundgren, JD, Chene, G, Miro, JM, Furrer, H & Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) 2010, 'Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count', Clinical Infectious Diseases, bind 51, nr. 5, s. 611-9. https://doi.org/10.1086/655761

@article{0d5feb8816a449d38ca91687006c8841,

title = "Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count",

abstract = "Current guidelines suggest that primary prophylaxis for Pneumocystis jiroveci pneumonia (PcP) can be safely stopped in human immunodeficiency virus (HIV)-infected patients who are receiving combined antiretroviral therapy (cART) and who have a CD4 cell count >200 cells/microL. There are few data regarding the incidence of PcP or safety of stopping prophylaxis in virologically suppressed patients with CD4 cell counts of 101-200 cells/microL.",

author = "Amanda Mocroft and Peter Reiss and Ole Kirk and Cristina Mussini and Enrico Girardi and Philippe Morlat and Christoph Stephan and \{De Wit\}, Stephane and Katja Doerholt and Jade Ghosn and Bucher, \{Heiner C\} and Lundgren, \{Jens D\} and Genevieve Chene and Miro, \{Jose M\} and Hansjakob Furrer and \{Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE)\}",

year = "2010",

month = sep,

day = "1",

doi = "10.1086/655761",

language = "English",

volume = "51",

pages = "611--9",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count

AU - Mocroft, Amanda

AU - Reiss, Peter

AU - Kirk, Ole

AU - Mussini, Cristina

AU - Girardi, Enrico

AU - Morlat, Philippe

AU - Stephan, Christoph

AU - De Wit, Stephane

AU - Doerholt, Katja

AU - Ghosn, Jade

AU - Bucher, Heiner C

AU - Lundgren, Jens D

AU - Chene, Genevieve

AU - Miro, Jose M

AU - Furrer, Hansjakob

AU - Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE)

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Current guidelines suggest that primary prophylaxis for Pneumocystis jiroveci pneumonia (PcP) can be safely stopped in human immunodeficiency virus (HIV)-infected patients who are receiving combined antiretroviral therapy (cART) and who have a CD4 cell count >200 cells/microL. There are few data regarding the incidence of PcP or safety of stopping prophylaxis in virologically suppressed patients with CD4 cell counts of 101-200 cells/microL.

AB - Current guidelines suggest that primary prophylaxis for Pneumocystis jiroveci pneumonia (PcP) can be safely stopped in human immunodeficiency virus (HIV)-infected patients who are receiving combined antiretroviral therapy (cART) and who have a CD4 cell count >200 cells/microL. There are few data regarding the incidence of PcP or safety of stopping prophylaxis in virologically suppressed patients with CD4 cell counts of 101-200 cells/microL.

UR - https://www.scopus.com/pages/publications/77955836995

U2 - 10.1086/655761

DO - 10.1086/655761

M3 - Journal article

C2 - 20645862

SN - 1058-4838

VL - 51

SP - 611

EP - 619

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 5

ER -

Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater